2-bromo-5-methoxy-4-(trifluoromethyl)aniline | 694514-19-7

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-5-methoxy-4-(trifluoromethyl)aniline
• CAS: 694514-19-7
• 化学式: C₈H₇BrF₃NO
• 分子量: 270.049
• InChiKey: NUFDHHXRRSOFSF-UHFFFAOYSA-N

物化性质

• 沸点：
  282.8±40.0 °C(Predicted)
• 密度：
  1.632±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-bromo-5-methoxy-4-(trifluoromethyl)aniline 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 溴 、 caesium carbonate 、 溶剂黄146 、 sodium t-butanolate 、 2-二-叔丁膦基-2',4',6'-三异丙基联苯 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 51.0h， 生成 tert-butyl N-[3-[4-(methanesulfonamido)phenyl]-5-methoxy-6-(trifluoromethyl)-8-quinolyl]carbamate
  参考文献：
  名称：

  Discovery of N-[4-[6-tert-Butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a Potent Inhibitor of the Hepatitis C Virus NS5B Polymerase

  摘要：

  In the past few years, there have been many advances in the efforts to cure patients with hepatitis C virus (HCV). The ultimate goal of these efforts is to develop a combination therapy consisting of only direct-antiviral agents (DAAs). In this paper, we discuss our efforts that led to the identification of a bicyclic template with potent activity against the NS5B polymerase, a critical enzyme on the life cycle of HCV. In continuation of our exploration to improve the stilbene series, the 3,5,6,8-tetrasubstituted quinoline core was identified as replacement of the stilbene moiety. 6-Methoxy-2(1H)-pyridone was identified among several heterocyclic headgroups to have the best potency. Solubility of the template was improved by replacing a planar aryl linker with a saturated pyrrolidine. Profiling of the most promising compounds led to the identification of quinoline 41 (RG7109), which was selected for advancement to clinical development.

  DOI：

  10.1021/jm401329s
• 作为产物：
  描述：

  3-甲氧基-4-(三氟甲基)苯胺 在 溶剂黄146 、 sodium carbonate 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 1.5h， 生成 2-bromo-5-methoxy-4-(trifluoromethyl)aniline
  参考文献：
  名称：

  HETEROCYCLIC ANTIVIRAL COMPOUNDS

  摘要：

  具有化学式I的化合物，其中R1、R2、R3、R4、X1、X2、X3和X4如本文所定义，是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了治疗HCV感染和抑制HCV复制的组合物和方法。

  公开号：

  US20100311760A1

文献信息

• DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS
  申请人：Brotherton-Pleiss Christine E.

  公开号：US20100160388A1

  公开（公告）日：2010-06-24

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

  公式I的化合物：或其药用可接受的盐，其中m、n、R1、R2、R3、R4和R5按本文件定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与P2X7嘌呤能受体相关疾病的方法。
• [EN] PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS<br/>[FR] PYRROLOPYRIMIDINE AMINES EN TANT QU'INHIBITEURS DU COMPLÉMENT
  申请人：BIOCRYST PHARM INC

  公开号：WO2021202977A1

  公开（公告）日：2021-10-07

  Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

  本文披露了式（I）的化合物及其药用盐，这些化合物是裂解系统的抑制剂。还提供了包含这种化合物的药物组合物，以及使用这些化合物和组合物治疗或预防由异常裂解系统活动特征的疾病或状况的方法。
• [EN] SULFONAMIDES<br/>[FR] SULFONAMIDES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2004043366A2

  公开（公告）日：2004-05-27

  The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
• [EN] DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS<br/>[FR] DIHYDROPYRIDONE URÉES EN TANT QUE MODULATEURS DE P2X7
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010072599A1

  公开（公告）日：2010-07-01

  Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, n, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.